FHOD3

Across TCGA pan-cancer cohorts, FHOD3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FHOD3 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FHOD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FHOD3 expression acts as an unfavorable survival marker.

HNSC, CCRCC, and LSCC are the cancer types where FHOD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.720	1.000	.009	27	view →
CCRCC	DFS	Median	II,III,IV	0.295	0.827	.010	15	view →
LSCC	DFS	Quartile	II,III,IV	0.583	1.000	.010	11	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FHOD3–HNSC (OS)

Open the HNSC breakdown →